Hypertonic saline in treatment of pulmonary disease in cystic fibrosis
about
Advances toward the elucidation of hypertonic saline effects on Pseudomonas aeruginosa from cystic fibrosis patientsDefective goblet cell exocytosis contributes to murine cystic fibrosis-associated intestinal disease.High-resolution mucociliary transport measurement in live excised large animal trachea using synchrotron X-ray imaging.D-BMAP18 Antimicrobial Peptide Is Active In vitro, Resists to Pulmonary Proteases but Loses Its Activity in a Murine Model of Pseudomonas aeruginosa Lung InfectionSalt, chloride, bleach, and innate host defense.Hypertonic saline is effective in the prevention and treatment of mucus obstruction, but not airway inflammation, in mice with chronic obstructive lung diseaseThe challenges and promises of new therapies for cystic fibrosis.Host mucin glycosylation plays a role in bacterial adhesion in lungs of individuals with cystic fibrosis.Efficacy and adverse effects of drugs used to treat adult cystic fibrosis.Easing the wheeze.Plasma membrane wounding and repair in pulmonary diseases.Nebulized hypertonic saline to prevent ventilator associated pneumonia in premature infants, a randomized trial.Effects of inhaled hypertonic (7%) saline on lung function test in preschool children with cystic fibrosis: results of a crossover, randomized clinical trial.Differential In Vitro and In Vivo Toxicities of Antimicrobial Peptide Prodrugs for Potential Use in Cystic Fibrosis.Functional lung MRI for regional monitoring of patients with cystic fibrosis.Development of an airway mucus defect in the cystic fibrosis rat.The use of pulmonary clearance medications in the acutely ill patient.Hypertonic Saline Suppresses NADPH Oxidase-Dependent Neutrophil Extracellular Trap Formation and Promotes Apoptosis.
P2860
Q28658389-97E4EDAA-8D2E-47D5-8B1B-C36DE956B655Q30628431-0E2F9085-C1BC-4FA7-90E1-419D2EF75E29Q30851151-75D5ADFD-31D7-457D-9835-B9A47963FE66Q33809988-4F8223B0-BBD4-467C-8B36-8238B29A0FE2Q36608150-5F685EE2-505A-4B47-8897-39861CBE7529Q37298002-A9414F60-EAED-49AA-A5E4-ED91B9C6288EQ38023386-A4EED5E4-09FC-460E-B05C-D4E4E02192B9Q38153821-A9ED9AD8-35C1-4DD8-8F79-21AFF4096C78Q38325672-17B1C99B-83F7-44CB-B53E-C1E2763FAA5EQ38569692-FEF38998-6642-4C12-AF2A-119F2EA9AE8AQ39071297-3B895BCB-36DF-4E4F-81AC-2E20122CE5E6Q40122209-A41DBCBB-1269-4CF1-83A4-AFE3AD91AEE1Q41030736-EFF4EF4F-7758-4E72-9AE9-F9E9E414C33DQ41289926-C42EAA54-1DA9-48D0-B4C1-F6A581BB0CF4Q47142409-6855A59B-69A9-483F-B083-3EA3AB6D9304Q47722821-3887F8E2-928B-483E-864B-B961B0847650Q47810242-DE5879AD-11EA-49C5-A153-719A289D93F7Q55233739-FADEFC0B-4275-45A2-93B0-B28FF8E5A489
P2860
Hypertonic saline in treatment of pulmonary disease in cystic fibrosis
description
im Mai 2012 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2012
@uk
name
Hypertonic saline in treatment of pulmonary disease in cystic fibrosis
@en
Hypertonic saline in treatment of pulmonary disease in cystic fibrosis
@nl
type
label
Hypertonic saline in treatment of pulmonary disease in cystic fibrosis
@en
Hypertonic saline in treatment of pulmonary disease in cystic fibrosis
@nl
prefLabel
Hypertonic saline in treatment of pulmonary disease in cystic fibrosis
@en
Hypertonic saline in treatment of pulmonary disease in cystic fibrosis
@nl
P2093
P2860
P921
P356
P1476
Hypertonic saline in treatment of pulmonary disease in cystic fibrosis
@en
P2093
Emer P Reeves
Kerstin Pohl
Kevin Molloy
Noel G McElvaney
P2860
P304
P356
10.1100/2012/465230
P407
P5008
P577
2012-05-03T00:00:00Z